March 5, 2007 -- Lilly will buy Hypnion, a privately held biotech that specializes in sleep disorder treatments; Arena began a Phase II trial of its new sedative, APD125; Myriad Genetics presented positive results from a Phase II trial of Flurizan for Alzheimer’s; Memory reported that MEM 1003 failed a Phase IIa trial for bipolar disorder; GlaxoSmithKline said its split antigen H5N1 vaccine was effective against diverse strains of avian flu; Iomai published positive results on its vaccine patch for travelers’ diarrhea; and Amgen received two upgrades based on valuation. The Centient Biotech 200™ dropped 33 points to 3789, a loss of .86%. More details...
